サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1594995

世界の研究用抗体市場

Research Antibodies

出版日
ページ情報
英文 93 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
世界の研究用抗体市場
出版日: 2024年11月22日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 93 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

研究用抗体の世界市場は2030年までに58億米ドルに達する見込み

2023年に42億米ドルと推定される研究用抗体の世界市場は、分析期間2023-2030年にCAGR 4.9%で成長し、2030年には58億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである試薬は、CAGR 4.6%を記録し、分析期間終了時には48億米ドルに達すると予測されます。抗体セグメントの成長率は、分析期間中CAGR 6.4%と推定されます。

米国市場は12億米ドルと推定、中国はCAGR 4.6%で成長すると予測

米国の研究用抗体市場は2023年に12億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR 4.6％を追いかけ、2030年までに10億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.3％と4.0％と予測されています。欧州では、ドイツがCAGR 3.7%で成長すると予測されています。

世界の研究用抗体市場- 主要動向と促進要因のまとめ

科学的発見に欠かせない研究用抗体とは？

研究用抗体は、特定のタンパク質に正確に結合する能力により、科学者が複雑な生物学的サンプル内の生体分子を検出、測定、操作できるようにする、生物学研究において不可欠なツールです。これらの抗体は、分子生物学、免疫学、腫瘍学、神経科学を含む様々な分野において、細胞プロセス、シグナル伝達経路、疾病メカニズムの調査を可能にする重要な役割を果たしています。抗体は、ウェスタンブロッティング、免疫組織化学（IHC）、酵素結合免疫吸着測定法（ELISA）などの手法で使用され、組織や細胞内のタンパク質やその他の抗原を同定します。これらの特異性と汎用性により、研究用抗体は基礎生物学と疾患病理学の理解を深めるために不可欠なものとなっています。

精密医療と個別化治療の時代には、分子レベルでの標的分析を可能にする研究用抗体はさらに重要なものとなっています。例えば、がん研究では、治療方針の決定や病気の進行をモニターするためのバイオマーカーを検出するために、抗体が頻繁に使用されています。このような詳細な分子プロファイリングを可能にすることで、研究用抗体は基礎科学と臨床応用の両方をサポートします。診断や治療の意思決定におけるバイオマーカーの重要性が高まるにつれ、高品質で信頼性の高い抗体への需要が高まっています。そのため、研究用抗体は科学的知識を深めるだけでなく、トランスレーショナルリサーチや臨床研究への応用を通じて、患者の転帰を改善するためにも不可欠なツールとなっています。

技術革新はどのように研究用抗体市場を形成しているか？

技術の進歩は、研究用抗体の能力と用途を大きく広げ、より特異的で安定した再現性のある抗体の開発につながりました。主要な技術革新の一つは、遺伝子クローニングと発現技術を用いて生産される組み換え抗体の開発です。従来のモノクローナル抗体とは異なり、リコンビナント抗体は一貫性が高く、バッチ間のばらつきがないため、実験的研究において信頼性が高いです。この一貫性は、正確な分析に再現性が不可欠な臨床や製薬のアプリケーションにおいて特に価値があります。さらに、組換え抗体は標的抗原に対してより高い特異性と親和性を持つように設計することができるため、オフターゲット効果の可能性が低くなり、実験結果の正確性が向上します。

もう一つの重要な技術的進歩は、ラクダ科の抗体に由来する単一ドメインの抗体、すなわち「ナノ抗体」の出現です。これらのナノボディは従来の抗体よりも小さく安定性が高いため、ライブセルイメージングや細胞内研究など、従来の抗体では大きすぎたり不安定だったりする用途に最適です。ナノボディは細胞内のターゲットにアクセスして結合する可能性があり、リアルタイムでタンパク質相互作用を研究する新たな可能性を開く。さらに、自動化とハイスループットスクリーニング技術により、抗体開発プロセスの迅速化と効率化が可能になり、研究者は大量の抗体ライブラリーをスクリーニングして最も効果的な候補を同定することができます。このような技術革新は、科学者たちに現代の研究ニーズの進化に合わせた幅広いツールを提供することで、研究用抗体市場を再形成しています。

研究用抗体市場に存在する課題と機会とは？

研究用抗体は科学的発見にとって非常に貴重なものですが、市場は製品の品質と再現性に関する大きな課題に直面しています。主な懸念事項のひとつは、市販されている抗体のすべてが、特異性と一貫性に関して要求される基準を満たしていないことです。バッチ間のばらつきや不十分なバリデーションは、信頼性の低い実験結果につながる一般的な問題であり、最終的には研究結果の信頼性に影響を与えます。さらに、非特異的結合や交差反応性の存在は、偽陽性や偽陰性を生じさせ、データの解釈を複雑にします。このような問題に対処し、科学研究の再現性を確保するために、標準化されたバリデーションプロトコールや抗体の性能に関する透明性の高いデータを求める声が、研究者や研究機関からますます高まっています。

しかし、こうした課題は、市場の成長と革新の機会にも拍車をかけています。各社は現在、製品の信頼性を研究者に保証するため、独立した第三者機関による試験を含め、厳格な品質管理とバリデーション・プロセスに投資しています。さらに、特定の研究ニーズに合わせてカスタマイズされた抗体ソリューションに対する需要が高まっています。カスタム抗体サービスは、研究者独自のターゲットや用途に最適化された抗体を、しばしば組み換え技術によって提供します。研究者が抗体の高水準化とカスタマイズを求めているため、市場はより専門的な提供とバリデーションの強化にシフトしています。さらに、より多くの学術機関や研究助成機関が再現性を重視する中、十分に検証された信頼性の高い抗体を提供できる企業は、競争上の優位性を獲得する態勢を整えています。

研究用抗体市場を加速する主な促進要因は？

研究用抗体市場の成長は、生物医学研究の進歩や高品質な研究ツールに対する需要の高まりを反映するいくつかの要因によって牽引されています。がん、自己免疫疾患、感染症などの疾病の蔓延が増加していることが、主要な促進要因の一つであり、研究者は疾病経路の研究、バイオマーカーの同定、潜在的な治療標的の開発のために抗体を求めています。例えばがん研究では、抗体は腫瘍の挙動を理解し、予後を評価し、個別化治療を設計するのに役立つ特定のタンパク質マーカーを同定するために広範囲に使用されています。薬剤の有効性を試験し、潜在的なオフターゲット効果をモニターするために使用される、薬剤開発における抗体の用途の拡大も、市場成長の促進要因となっています。

また、学術機関、製薬会社、政府機関による研究開発への投資が拡大していることも主な促進要因となっています。新しい治療法や診断ツールの需要が高まるにつれて、生物医学研究への資金が増加し、研究用抗体の堅調な市場が形成されています。さらに、創薬におけるハイスループットスクリーニング技術の採用が増加しており、大規模な研究に使用できる信頼性の高い抗体の需要がさらに高まっています。ゲノミクスやプロテオミクスのような分野の進歩に伴い、幅広いタンパク質を標的とし、詳細な分子解析を可能にする抗体へのニーズも高まっています。最後に、特に北米や欧州などの地域では、生物医学研究を支援する政府の政策が市場を強化しており、この分野の持続的な成長と技術革新に貢献しています。

セグメント

製品（試薬、抗体）、技術（ウェスタンブロッティング、フローサイトメトリー、酵素結合免疫吸着測定法（ELISA）、免疫組織化学、免疫蛍光、免疫沈降、その他の技術）、用途（腫瘍学、感染症、免疫学、幹細胞、神経生物学、その他の用途）、最終用途（製薬・バイオテクノロジー企業、学術・研究機関、CRO（医薬品開発業務受託機関））。

調査対象企業の例（全42件）

  • Abcam plc
  • Active Motif, Inc.
  • Affinity Biologicals, Inc.
  • Agilent Technologies, Inc.
  • BD
  • Beckman Coulter, Inc.
  • Bethyl Laboratories, Inc.
  • Bio SB
  • BioLegend, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Enzo Life Sciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • GenScript
  • Jackson ImmunoResearch Inc.
  • Lonza
  • Merck KGaA
  • Miltenyi Biotec
  • OriGene Technologies, Inc.
  • PerkinElmer Inc.
  • QIAGEN
  • Rockland Immunochemicals, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP22701

Global Research Antibodies Market to Reach US$5.8 Billion by 2030

The global market for Research Antibodies estimated at US$4.2 Billion in the year 2023, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Reagent, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Antibodies segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 4.6% CAGR

The Research Antibodies market in the U.S. is estimated at US$1.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 4.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Research Antibodies Market - Key Trends & Drivers Summarized

What Makes Research Antibodies Vital in Scientific Discovery?

Research antibodies are essential tools in biological research, utilized for their ability to precisely bind to specific proteins, allowing scientists to detect, measure, and manipulate biomolecules within complex biological samples. These antibodies play a critical role across various fields, including molecular biology, immunology, oncology, and neuroscience, as they enable researchers to investigate cellular processes, signaling pathways, and disease mechanisms. Antibodies are used in techniques such as Western blotting, immunohistochemistry (IHC), and enzyme-linked immunosorbent assay (ELISA), among others, to identify proteins or other antigens in tissues and cells. Their specificity and versatility make research antibodies indispensable for advancing our understanding of fundamental biology and disease pathology.

In the era of precision medicine and personalized therapies, research antibodies have become even more crucial as they allow for targeted analysis at the molecular level. For instance, in cancer research, antibodies are frequently used to detect biomarkers that inform treatment decisions and monitor disease progression. By enabling such detailed molecular profiling, research antibodies support both basic science and clinical applications. With the growing importance of biomarkers in diagnostics and therapeutic decision-making, the demand for high-quality, reliable antibodies is on the rise. This makes research antibodies essential tools not only for advancing scientific knowledge but also for improving patient outcomes through their application in translational and clinical research.

How Are Technological Innovations Shaping the Research Antibodies Market?

Technological advancements have greatly expanded the capabilities and applications of research antibodies, leading to the development of more specific, stable, and reproducible antibodies. One of the major innovations is the development of recombinant antibodies, which are produced using gene cloning and expression techniques. Unlike traditional monoclonal antibodies, recombinant antibodies offer higher consistency and are not subject to batch-to-batch variability, making them more reliable for experimental research. This consistency is particularly valuable in clinical and pharmaceutical applications, where reproducibility is essential for accurate analysis. Additionally, recombinant antibodies can be engineered to have higher specificity and affinity for target antigens, reducing the likelihood of off-target effects and improving the accuracy of experimental results.

Another significant technological advancement is the emergence of single-domain antibodies, or "nanobodies," derived from camelid antibodies. These nanobodies are smaller and more stable than traditional antibodies, making them ideal for applications where traditional antibodies may be too large or unstable, such as in live-cell imaging and intracellular studies. Nanobodies have the potential to access and bind to targets within cells, opening new possibilities for studying protein interactions in real time. Furthermore, automation and high-throughput screening technologies are enabling faster and more efficient antibody development processes, allowing researchers to screen large libraries of antibodies to identify the most effective candidates. These innovations are reshaping the research antibodies market by providing scientists with a wider range of tools tailored to the evolving needs of modern research.

What Challenges and Opportunities Exist in the Research Antibodies Market?

While research antibodies are invaluable to scientific discovery, the market faces significant challenges related to product quality and reproducibility. One of the primary concerns is that not all commercially available antibodies meet the required standards for specificity and consistency. Batch-to-batch variability and inadequate validation are common issues that can lead to unreliable experimental results, ultimately impacting the credibility of research findings. Furthermore, the presence of non-specific binding or cross-reactivity can produce false positives or negatives, complicating data interpretation. Researchers and institutions increasingly call for standardized validation protocols and transparent data on antibody performance to address these issues and ensure reproducibility in scientific research.

However, these challenges have also spurred opportunities for growth and innovation in the market. Companies are now investing in rigorous quality control and validation processes, including independent third-party testing, to assure researchers of the reliability of their products. Additionally, there is an increasing demand for customized antibody solutions tailored to specific research needs. Custom antibody services provide researchers with antibodies that are optimized for their unique targets and applications, often through recombinant techniques. As researchers seek higher standards and customization in antibodies, the market is shifting toward more specialized offerings and enhanced validation. Furthermore, as more academic institutions and research funding bodies emphasize reproducibility, companies that can deliver well-validated and reliable antibodies are poised to gain a competitive advantage.

What Are the Key Drivers Accelerating the Research Antibodies Market?

The growth in the research antibodies market is driven by several factors, reflecting advancements in biomedical research and the rising demand for high-quality research tools. The increasing prevalence of diseases such as cancer, autoimmune disorders, and infectious diseases is one of the primary drivers, as researchers seek antibodies to study disease pathways, identify biomarkers, and develop potential therapeutic targets. In cancer research, for example, antibodies are used extensively to identify specific protein markers that help researchers understand tumor behavior, assess prognosis, and design personalized treatments. The expanding application of antibodies in drug development, where they are used to test drug efficacy and monitor potential off-target effects, is also driving market growth.

Another key driver is the growing investment in research and development by academic institutions, pharmaceutical companies, and government agencies. As the demand for new therapies and diagnostic tools rises, funding for biomedical research has increased, creating a robust market for research antibodies. Additionally, the increasing adoption of high-throughput screening techniques in drug discovery is further boosting the demand for reliable antibodies that can be used in large-scale studies. With advances in fields like genomics and proteomics, there is also a rising need for antibodies that can target a broad range of proteins, enabling detailed molecular analysis. Finally, government policies that support biomedical research, particularly in regions like North America and Europe, have strengthened the market, helping to ensure sustained growth and innovation in the research antibodies sector.

SCOPE OF STUDY:

The report analyzes the Research Antibodies market in terms of US$ Million by the following Application; End-Use; Product; Technology, and Geographic Regions/Countries:

Segments:

Product (Reagent, Antibodies); Technology (Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation, Other Technologies); Application (Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology, Other Applications); End-Use (Pharma & Biotech Companies, Academic & Research Institutions, Contract Research Organizations (CROs))

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Abcam plc
  • Active Motif, Inc.
  • Affinity Biologicals, Inc.
  • Agilent Technologies, Inc.
  • BD
  • Beckman Coulter, Inc.
  • Bethyl Laboratories, Inc.
  • Bio SB
  • BioLegend, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Enzo Life Sciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • GenScript
  • Jackson ImmunoResearch Inc.
  • Lonza
  • Merck KGaA
  • Miltenyi Biotec
  • OriGene Technologies, Inc.
  • PerkinElmer Inc.
  • QIAGEN
  • Rockland Immunochemicals, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Research Antibodies - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Prevalence of Chronic Diseases and Cancer Drives Demand for Research Antibodies in Diagnostics and Therapeutics
    • Increasing Investment in Biomedical Research Expands Addressable Market for High-quality Research Antibodies
    • Advancements in Recombinant Antibody Technology Enhance Consistency and Reproducibility, Strengthening Demand
    • Rising Focus on Precision Medicine Spurs Need for Specific and Customizable Antibody Solutions
    • Expansion of Proteomics and Genomics Research Drives Adoption of Antibodies for Target Identification and Validation
    • Increased Use of Antibodies in Drug Discovery Pipelines Propels Demand for Functional and High-affinity Antibodies
    • Technological Innovations in Antibody Production Streamline Manufacturing and Accelerate Market Growth
    • Growing Adoption of Antibodies in Diagnostic Assays Expands Market for Disease-specific and Marker-specific Antibodies
    • Rising Demand for Monoclonal and Polyclonal Antibodies in Academic Research Institutions Supports Market Growth
    • Emerging Applications of Antibodies in Neuroscience and Immunology Foster Development of Specialized Antibody Products
    • Increased Collaboration Between Antibody Manufacturers and Pharmaceutical Companies Drives Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Research Antibodies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Research Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Research Antibodies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Reagent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Reagent by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Western Blotting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Western Blotting by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Flow Cytometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Flow Cytometry by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Immunofluorescence by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Immunofluorescence by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Immunoprecipitation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Immunoprecipitation by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 25: World 7-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World 7-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World 7-Year Perspective for Stem Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Neurobiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 31: World 7-Year Perspective for Neurobiology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 35: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 37: World 7-Year Perspective for Academic & Research Institutions by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: World 7-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 40: USA Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 41: USA 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 42: USA Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 43: USA 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 46: USA Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: USA 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • CANADA
    • TABLE 48: Canada Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Canada 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 52: Canada Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 53: Canada 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 54: Canada Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Canada 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • JAPAN
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 58: Japan Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Japan 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 60: Japan Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Japan 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • CHINA
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 64: China Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 65: China 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 66: China Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 67: China 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 70: China Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 71: China 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • EUROPE
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Research Antibodies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 73: Europe 7-Year Perspective for Research Antibodies by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 76: Europe Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Europe 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 78: Europe Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 79: Europe 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • FRANCE
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 82: France Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 83: France 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 84: France Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 85: France 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 88: France Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 89: France 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • GERMANY
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 90: Germany Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Germany 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 94: Germany Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 95: Germany 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 96: Germany Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 97: Germany 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 100: Italy Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 101: Italy 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 102: Italy Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 103: Italy 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • UNITED KINGDOM
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 106: UK Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 107: UK 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 108: UK Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 109: UK 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 112: UK Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 113: UK 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 115: Rest of Europe 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 119: Rest of Europe 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 121: Rest of Europe 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 125: Asia-Pacific 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 127: Asia-Pacific 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 130: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 131: Rest of World 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
    • TABLE 132: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 133: Rest of World 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
    • TABLE 136: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 137: Rest of World 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030

IV. COMPETITION